ストックスクリーナーアプリを入手
9.09
1.52%
-0.14
プレマーケット:
8.84
-0.25
-2.75%
Entrada Therapeutics Inc (TRDA) 最新ニュース
Barclays PLC Has $887,000 Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Invesco Ltd. Takes Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics (TRDA) Projected to Post Earnings on Tuesday - Defense World
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for - MSN
Arvinas, Entrada cut staff; Merck builds US hub for Keytruda - BioPharma Dive
Legal & General Group Plc Has $344,000 Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Immunic’s stock falls on multiple sclerosis data; Entrada’s layoffs - Endpoints News
JPMorgan Chase & Co. Raises Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics IncApproves Strategic Plan Focusing On DMD ProgramsSEC Filing - marketscreener.com
Russell Investments Group Ltd. Raises Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Geode Capital Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
LPL Financial LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Trend Tracker for (TRDA) - news.stocktradersdaily.com
Vanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
CandE Benchmark Research Case Study – Entrada Therapeutics - ere.net
KLP Kapitalforvaltning AS Invests $36,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
American Century Companies Inc. Purchases 8,985 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? - Yahoo Finance
HC Wainwright Issues Negative Forecast for TRDA Earnings - MarketBeat
Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) 27% Price Drop - simplywall.st
HC Wainwright Issues Pessimistic Forecast for TRDA Earnings - Defense World
(TRDA) On The My Stocks Page - news.stocktradersdaily.com
Entrada Therapeutics (NASDAQ:TRDA) Receives Buy Rating from HC Wainwright - Defense World
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals - TipRanks
Entrada Therapeutics stock rating holds with $20 target By Investing.com - Investing.com UK
Entrada Therapeutics stock hits 52-week low at $9.74 By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Roth/MKM maintains Buy on Entrada stock, $23 target By Investing.com - Investing.com Canada
Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment - TipRanks
Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK (TRDA:NASDAQ) - Seeking Alpha
Entrada Therapeutics rises on UK approval for muscle-wasting drug study - TradingView
Entrada’s ENTR-601-45 gains clearance in UK to enter clinic for Duchenne muscular dystrophy - BioWorld MedTech
Entrada Therapeutics begins Duchenne study in UK By Investing.com - Investing.com Australia
Entrada Therapeutics begins Duchenne study in UK - Investing.com India
Entrada Therapeutics Gains UK Approval for DMD Study - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - The Manila Times
Major Breakthrough: Entrada's DMD Drug Gets Green Light for UK Clinical Trials - Stock Titan
Bank of New York Mellon Corp Lowers Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics stock hits 52-week low at $10.21 - Investing.com
Entrada Therapeutics stock hits 52-week low at $10.21 By Investing.com - Investing.com UK
Entrada Therapeutics CFO sells $19,035 in stock By Investing.com - Investing.com South Africa
Entrada Therapeutics CFO sells $19,035 in stock - Investing.com India
Long Term Trading Analysis for (TRDA) - news.stocktradersdaily.com
Entrada Therapeutics stock hits 52-week low at $10.25 By Investing.com - Investing.com Australia
Entrada Therapeutics stock hits 52-week low at $10.25 - Investing.com
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday - Defense World
Entrada Therapeutics stock hits 52-week low at $11.3 amid market shifts - Investing.com Canada
Brokers Offer Predictions for TRDA Q4 Earnings - Defense World
What is William Blair’s Estimate for TRDA Q1 Earnings? - Defense World
0.39%
3.66%
大文字化:
|
ボリューム (24 時間):